Most Read Articles
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.

The US.FDA. Authorizes the Marketing of IQOS Tobacco Heating System with “Reduced Exposure” Information

28 Aug 2020
The U.S. Food and Drug Administration (FDA) has authorized the marketing of Philip Morris Products S.A.’s “IQOS Tobacco Heating System”* as modified risk tobacco products (MRTP) with the “exposure modification” order.
This is the first tobacco product that has ever been authorized by the FDA to be marketed with the information of “reduced exposure” (of the body to harmful chemicals). The authorization permits the marketing of a product as it contains a reduced level of a substance or it presents a reduced exposure to a substance or as it is free of a substance, and the issuance of the order is expected to benefit the health of the population as a whole.
According to Mitch Zeller, J.D., Director of the FDA’s Center for Tobacco Products, data submitted by Philip Morris Products S.A. showed that marketing the IQOS Tobacco Heating System with the authorized information could help addicted adult smokers transition away from combusted cigarettes, thereby reducing their exposure to harmful chemicals if they completely switch to these products.
(* This product has been authorized to be marketed in USA, and has not yet officially commercialized in Vietnam)
Editor's Recommendations
Most Read Articles
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.